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Abstract: The activity of fumagillin, a mycotoxin produced by Aspergillus fumigatus, has not been
studied in depth. In this study, we used a commercial fumagillin on cultures of two cell types
(A549 pneumocytes and RAW 264.7 macrophages). This toxin joins its target, MetAP2 protein,
inside cells and, as a result, significantly reduces the electron chain activity, the migration, and
the proliferation ability on the A549 cells, or affects the viability and proliferation ability of the
RAW 264.7 macrophages. However, the toxin stimulates the germination and double branch hypha
production of fungal cultures, pointing out an intrinsic resistant mechanism to fumagillin of fungal
strains. In this study, we also used a fumagillin non-producer A. fumigatus strain (∆fmaA) as well as its
complemented strain (∆fmaA::fmaA) and we tested the fumagillin secretion of the fungal strains using
an Ultra High-Performance Liquid Chromatography (UHPLC) method. Furthermore, fumagillin
seems to protect the fungus against phagocytosis in vitro, and during in vivo studies using infection
of immunosuppressed mice, a lower fungal burden in the lungs of mice infected with the ∆fmaA
mutant was demonstrated.
Keywords: fumagillin; Aspergillus fumigatus; virulence factor; pathogenesis; RAW 264.7; A549; mice
infection; UHPLC
1. Introduction
Aspergillus fumigatus is a saprophytic fungus that can colonize diverse ecological
niches facilitated by its great plasticity to adapt to different environments and the wide
dispersal of its small, airborne spores called conidia [1,2]. The conidia allow A. fumigatus to
reach all chambers of the human respiratory tract, where the fungus is able to cause a wide
range of infections depending on the immune status of the patient [3–6].
The biological characteristics that allow A. fumigatus to colonize and/or infect the
respiratory tract are known as virulence factors. These include the fungal cell wall and
the proteins involved in its formation, the resistance of the conidia to ultraviolet radia-
tion and dryness, the mechanisms to evade the immune response, and the production
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of proteases and toxins [6]. In fact, the A. fumigatus genome contains a great variety of
biosynthetic clusters [7,8] that provide the fungus with complex and bioactive secondary
metabolites, including the production of toxins [9–11]. Among the variety of toxins pro-
duced by A. fumigatus, several have been linked with enhanced virulence and include
gliotoxin [12–15], fumitremorgin A and B [16,17], hexadehydroastechrome [18], hemolysin,
and mitogillin [19].
The role of fumagillin in fungal virulence has not been completely elucidated yet. This
toxin has been widely studied for other reasons, such as tumor control due to the inhibition
of endothelial cell proliferation and its effect as an anti-tumor molecule [20]. Furthermore,
it has been used as an antibiotic agent in the treatment against different pathogens, such
as microsporidia, parasites, and as a treatment of diseases such as AIDS and obesity [21].
The mycotoxin is produced by a series of enzymes encoded in a biosynthetic cluster
located on chromosome 8 of A. fumigatus [22]. The members of the biosynthetic cluster are
overexpressed in the lungs of intranasally infected mice [23] and include the fumagillin
pathway-specific transcription factor [24]. In fact, a non-fumagillin producer mutant strain
caused significantly less cellular damage than the wild type in vitro, demonstrating a
potential relevance of this toxin in virulence [23].
Given these previous data and the need to deeply analyze the involvement of sec-
ondary metabolites in virulence [25], the aim of the present study was to assess the role
of fumagillin in the pathogenesis of A. fumigatus. For this purpose, we studied the effect
of commercial fumagillin on A. fumigatus itself, macrophages, and epithelial cells. Ad-
ditionally, a non-fumagillin producer mutant strain was used in co-incubation with cell
cultures and during murine infection to determine the potential impact of the toxin on
fungal virulence.
2. Materials and Methods
2.1. Aspergillus fumigatus Strains, Media, and Growth Conditions
The ∆akuBku80 strain of A. fumigatus was used as a wild-type (Wt) strain during this
study. Furthermore, we used the previously published [22] deletion mutant strain ∆fmaA
(a non-fumagillin producer strain) and its complemented strain ∆fmaA::fmaA [23]. All the
strains were grown on glucose minimal medium agar (GMM) for seven days at 37 ◦C, as
previously described [26]. Conidia were harvested and cleaned twice with saline-Tween
solution (SS-T; 0.9% NaCl and 0.02% Tween 20). The number of conidia for each experiment
was adjusted using a Bürker counting chamber.
2.2. Aspergillus fumigatus Phenotypic Characterization
The phenotypes of the mutant A. fumigatus strains used in this work were evaluated
using the spot dilution assay protocol, as previously described [27]. Briefly, we supple-
mented GMM medium with 80 µg/mL congo red (CR), 40 µg/mL calcofluor white (CW)
or 0.0125% sodium dodecyl sulfate (SDS) as cell wall/membrane stress agents; 1 M NaCl,
1 M KCl, or 1.2 M sorbitol as osmotic stress agents; or hydrogen peroxide (30%, 15%, 7.5%,
and 3.75% v/v) as an oxidative stress agent.
2.3. Cell Lines
Two different cell lines obtained from the American Type Culture Collection (ATCC,
Manassas, VA, USA) were used in this study: the murine macrophage cell line RAW 264.7
and the human alveolar epithelial cell line A549. Cell cultures were maintained in RPMI
1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 200 mM
L-glutamine, 100 U/mL penicillin, and 0.1 mg/mL streptomycin (complete RPMI), and
incubated at 37 ◦C, 5% CO2, and 95% of humidity (cell culture atmosphere). Cell line
passages were used only when the viability of the cells was higher than 90%. All culture
media components were from Sigma–Aldrich (St. Louis, MO, USA).
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2.4. Isolation and Culture of Mouse Primary Macrophages
Mouse bone marrow-derived macrophages (BMMs) were generated following the
method previously published using 8–12 week-old C57Bl/6 mice [28]. Briefly, bone marrow
material was obtained by flushing mouse femurs and tibias in complete RPMI. The cell
suspensions were filtered through a 70 µm-nylon mesh (ThermoFisher, Waltham, MA,
USA) and then centrifuged at 400 rpm for 5 min. Then, ammonium–chloride–potassium
(ACK) lysis buffer was used to remove red blood cells. The remaining cells were incubated
in untreated 100 mm × 15 mm Petri dishes for 7 days in the presence of complete RPMI
supplemented with 30 ng/mL of M-CSF (Miltenyi Biotec, Bergisch Gladbach, Germany).
Fresh medium was added after 3 days of culture.
2.5. Quantification of Fumagillin Secretion by Aspergillus fumigatus
To study the ability of each fungal strain to produce fumagillin, we seeded 5 × 106 conidia/mL
of each strain in 2 mL of complete RPMI using 6-well plates (ThermoFisher). The plates were
incubated at 37 ◦C, 5% CO2, and 95% humidity. After 48 h of incubation, we centrifuged an aliquot
of 1 mL at 14,000 rpm for 5 min, and the supernatant was transferred to a light-safe microtube
and kept on ice until its measurement by UHPLC. Each assay was done using four independent
conidia batches of each strain harvested just before the assay start point.
2.6. Fungal Response to Increasing Concentrations of Fumagillin
To study if fumagillin affects fungal strains, we performed an 8 h germination study
in the presence of 0.5, 1, and 2 µg/mL of fumagillin. We seeded 2 × 106 conidia/well using
24 cell culture well plates. In each case, we calculated fungal germination and hyphal
branching using a Nikon Eclipse TE2000-U inverted microscope.
Growth curves of the fungal strains were assessed for 70 h in 96-well plates (Ther-
moFisher, Waltham, MA, USA). We seeded 5 × 105 fresh conidia per well in 150 µL of
MM supplemented with 0.5, 1, and 2 µg/mL of fumagillin. The plate was incubated in
the microplate reader SynergyTM HT (BioTek, Winooski, VT, USA) at 37 ◦C, and automatic
absorbance measures at 600 nm were done each 30 min for 70 h.
2.7. Fumagillin Absorption Ability by Cell Lines
To study the absorption of fumagillin by mammalian cells, we seeded 1 × 106 cells/mL
of the RAW 264.7 and A549 cell lines in a final volume of 2 mL of complete RPMI using
6-well plates. After 1 h of incubation to allow cell attachment, we replaced the medium
with 2 mL of complete RPMI supplemented with 1 µg/mL of fumagillin (Sigma–Aldrich).
Aliquots of 500 µL were collected after 8, 20, and 24 h of cell exposition in light-safe mi-
crotubes and processed as previously indicated until its measurement by UHPLC (Waters,
Milford, CT, USA).
In order to study whether fumagillin binds to the cell line instead of being degraded,
we grew RAW 264.7 and A549 cells in the presence of 2 µg/mL of toxin. After 24 h of
exposition, we discarded the supernatants and, after a saline solution wash, we lysed the
cells using 1 mL of RIPA buffer. Finally, we centrifuged the samples at 14,000 rpm for 5 min,
and the supernatants were measured using the UHPLC method. A toxin degradation
study was done by exposition of a 1 µg/mL fumagillin solution to different environmental
conditions as 80 ◦C or exposition to light for 96 h and exposition to pH 1.
2.8. Quantification of Fumagillin by UHPLC (Ultra High-Performance Liquid Chromatography)
in RPMI Samples
Quantitative analysis of fumagillin was carried out using an Acquity Ultra-High-
Performance Liquid Chromatography (UHPLC) system (Waters, Milford, CT, USA) cou-
pled to a photodiode array (PDA) detector, following a methodology previously pub-
lished [29]. The chromatographic separation was performed on an Acquity BEH C18
column (2.1 mm × 50 mm, 1.7 µm) from Waters. The mobile phases used were a 10 mM am-
monia/ammonium buffer (pH 10) as the aqueous mobile phase (A) and acetonitrile as
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the organic modifier (B). A flow rate of 0.40 mL/min was used with an elution gradient
as follows: 0–0.5 min, 20% B; 0.5–5.5 min, linear change from 20% to 95% B; 5.5–6.5 min,
95% B; 6.5–7.0 min, from 95% to 20%. During the chromatographic analysis, the column
was maintained at 35 ◦C with a thermostat, and the samples were kept at 4 ◦C in the
autosampler. Wavelengths of 336 and 280 nm were employed for fumagillin and diclofenac
(internal standard, IS), respectively. System control, data collection, and data processing
were accomplished using Empower 2 software.
Prior to the chromatographic analysis, a solid-phase extraction (SPE) procedure was
applied to the RPMI samples. Each 500 µL RPMI sample was spiked with 25 µL of
20 mg/mL IS solution in methanol and 475 µL of phosphate buffer (100 mM, pH 12). After
vortex mixing, the solution was transferred to Oasis MAX cartridges (30 mg, 1 cm3) from
Waters. The cartridges had been previously activated with 1 mL methanol and conditioned
with 1 mL phosphate buffer (100 mM, pH 12). After sample loading, the cartridges were
washed with 1 mL phosphate buffer (100 mM, pH 12):methanol (55:45) followed by 5 min
drying at high vacuum, and then 1 mL of 3.5% formic acid solution in methanol was used
for eluting the analyte. Subsequently, 500 µL of aqueous mobile phase was added to 500 µL
of the eluate, and after centrifugation, the solution was transferred to autosampler vials
and injected into the UHPLC system for analysis. For the quantification of fumagillin, a
calibration curve in RPMI was built with a linear range between 25 and 1500 µg/L.
2.9. Cellular Electron Transport Chain Activity
The electron transport chain (ETC) activity of cells in contact with different concen-
trations of fumagillin was measured using an MTT assay. Briefly, we seeded 8 × 104 cells
per well (RAW 264.7 or A549) in 96-well plates (ThermoFisher) with 150 µL of complete
RPMI. After 2 h of incubation to allow cell attachment, we replaced the complete RPMI
with 150 µL of RPMI supplemented with different concentrations of fumagillin (0, 0.5, 1,
and 2 µg/mL), and the cells were incubated using the abovementioned conditions of cell
culture atmosphere. After 24 h of incubation, we eliminated the medium, and we added
150 µL/well of complete RPMI supplemented with 0.5 mg/mL of MTT (Sigma–Aldrich)
and the plate was incubated for 4 h to allow the reduction of the tetrazolium dye MTT to
formazan crystals. Finally, we replaced MTT solution with 150 µL of DMSO in order to
dissolve formazan crystals, and after 15 min, the absorbance was measured at 560 nm using
a microplate reader SynergyTM HT (BioTek, Winooski, VT, USA). Results were expressed
as a percentage of metabolic activity.
2.10. Wound Healing Assay
In order to evaluate the growth inhibitory capacity of fumagillin over A549 epithelial
cells, we performed wound healing assays. Briefly, 1.5 × 105 cells per well were seeded
in 24-well plates and, after an incubation of 24 h, confluent monolayers were obtained.
Using a 1000 µL pipette tip, a vertical and a horizontal scratch was made and then washed
twice with PBS to remove detached cells. Then, fresh medium alone or containing 0.5, 1,
or 2 µg/mL of fumagillin was added to the cultures. Images were taken from one field of
view down between the intersection of the two scratches at 24 and 48 h after fumagillin
addition, using a Nikon Eclipse TE2000-U (Nikon, Minato, Tokyo, Japan) inverted micro-
scope. Finally, the percentage of scratch reduction was calculated and normalized to the
untreated control.
2.11. Analysis of Cell Proliferation and Viability by Flow Cytometry
Flow cytometry-based assays were carried out in the general services from the Univer-
sity of the Basque Country (SGIker, UPV/EHU) using a Beckman Coulter Gallios cytometer
(Beckman Coulter, Brea, CA, USA).
Changes in cell proliferation of A549 and RAW 264.7 cells in the presence of fumagillin
at different concentrations were determined using the fluorescent dye CFSE (Invitrogen,
Carlsbad, CA, USA). Cells were stained using 2 µM of CFSE in PBS for 30 min at 37 ◦C
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and 5% CO2 and then washed twice in RPMI supplemented with 1% of FBS. Finally, we
seeded 1 × 105 cells/well in 6-well plates. At time 0 h, the just stained cells were analyzed
in the flow cytometer (517 nm) alongside a set of unstained cells. Then, cells were exposed
to 0.5, 1, or 2 µg/mL of fumagillin, or left untreated. The study was extended for 72 h,
and daily samples were analyzed by flow cytometry. For that, cells were detached from
each well using a cell scraper and resuspended in RPMI. The flow cytometer was set up to
analyze 10,000 events from each sample, exciting the sample at 492 nm and measuring the
fluorescence at 517 nm. In order to calculate the statistical differences between conditions,
the average fluorescence of the cells without treatment was compared with the average
fluorescence of the cells treated with the abovementioned fumagillin concentrations.
On the other hand, cell viability assays were carried out using Propidium Iodide Ready
Flow™ Reagent (Invitrogen, Carlsbad, CA, USA) for 15 min following the manufacturer’s
instructions. Cell density, detachment protocol, and the number of cells analyzed in each
run were the same as in the proliferation assays. After cell staining, samples were excited
at 535 nm, following the manufacturer’s instructions, and the emission was at 617 nm.
Results were expressed as a percentage of cell viability.
2.12. Phagocytosis Assay and Fungal Growth
To analyze the interactions of the fungal strains with RAW 264.7 macrophages and
BMMs, we seeded 2 × 105 cells/mL in 500 µL of complete RPMI using 24-well plates (Ther-
moFisher) which contained 12 mm-diameter coverslips (ThermoFisher). After overnight
incubation, immune cells were co-cultured with A. fumigatus conidia of each strain (Wt,
∆fmaA, ∆fmaA::fmaA) at a multiplicity of infection of 10 (ten conidia per immune cell).
In parallel, we seeded the same number of each fungal strain conidia but in this case
without immune cells to analyze fungal growth in the absence of murine cells. At each
incubation time (2, 4, 6, and 8 h), we removed the coverslip to a new plate in order to
calculate the percentage of phagocytosis, fungal germination, and hyphal branching. For
that purpose, a minimum of 500 fungal cells was counted using a Nikon Eclipse TE2000-U
inverted microscope.
Furthermore, we performed the same phagocytosis assay under two additional con-
ditions. The first one, using RAW 264.7 macrophages pre-treated for 24 h with 1 µg/mL
of fumagillin (before the co-incubation) to determine the effect of the toxin itself, and the
second one using heat-inactivated conidia (121 ◦C for 30 min) of each A. fumigatus strain to
ensure that the genetic manipulation of the strains did not produce structural changes of
the conidia.
On the other hand, to study changes in the hyphal length of strains when growing
alone or combined with either of the macrophage models, we performed CW staining on
coverslips after 8 h of incubation. For that, samples were washed with PBS and stained
with 100 µL of CW solution for 20 min in the dark and at room temperature. Finally, we
washed the coverslips again with PBS, and they were mounted for fluorescence microscopy.
Ten micrographs per coverslip were taken randomly using an Eclipse Ni microscope
fluorescence microscope and a Nikon Ds-Fi2 camera (Nikon). Image analysis was carried
out using ImageJ software.
2.13. Mouse Model of Pulmonary Aspergillosis
Mice used in this study were kept in the General Animal Unit Service of the University
of the Basque Country (SGIker, UPV/EHU), with water and food ad libitum, handled in
biological safety cabinets, and kept in sterilized cages with negative-pressure ventilation
and filters.
SWISS female mice weighing 25–35 g were used in this study. All mice were immuno-
suppressed by the daily administration of 100 mg/kg cyclophosphamide (Sigma–Aldrich),
starting four days before infection. Five animals per group were infected intranasally with
20 µL SS-T solution containing 1 × 107 resting conidia of one A. fumigatus strain, either Wt,
∆fmaA or ∆fmaA::fmaA. Two independent experiments were performed.
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Mice were monitored daily to analyze changes in weight and clinical scores due to
the infection process. Clinical scoring was performed using a scale of 0–10, in which we
evaluated different aspects of the disease (Table S1) following the recommendations of
experts from our institution animal facility and the ethical committee members. Those mice
that reached humane endpoints (10 points) were euthanized to minimize mice suffering,
and their cause of death was considered as fungal infection.
To study the fungal burden in mice lungs, organs were extracted and were homoge-
nized in 1 mL of SS-T by vortexing in a tube in the presence of a sterile glass stick. Finally,
an aliquot of 0.1 mL was inoculated in potato dextrose agar plates supplemented with
10 µg/mL chloramphenicol and 25 µg/mL gentamicin (both from Sigma–Aldrich). Plates
were incubated at 37 ◦C, and the number of Colony-Forming Units (CFUs) was determined
after 3 days.
2.14. Statistics
All the assays were done at least by triplicate in three independent days. All statistical
analyses of this study were performed using GraphPad Prism 7 software (GraphPad
Software Inc., San Diego, CA, USA). At least three biological replicates were performed
to measure each parameter in each experimental condition; any statistically significant
differences were analyzed as required. All data present in this study followed a normal
distribution. t-test or ANOVA was used to study differences between conditions depending
on if we compared punctual data or multiple comparisons, respectively.
3. Results
3.1. Characterization of A. fumigatus Strains: Phenotype and Ability to Produce and
Tolerate Fumagillin
To monitor any potential effect of loss of fumagillin synthesis in A. fumigatus, a
phenotypic characterization following the spot dilution protocol was performed. Our
results did not show any significant difference between the Wt, ∆fmaA, and ∆fmaA::fmaA
strains under the different structural, osmotic, and oxidative stresses tested (Figure S1).
The fungal strains’ ability to secrete fumagillin was also studied by UHPLC using a
fixed concentration of toxin (0.2 µg/mL) as an internal control (Figure 1A). Consistent with
previous results, the ∆fmaA strain was unable to produce fumagillin in vitro. In contrast,
the Wt strain produced an average concentration of 0.43 µg/mL fumagillin (Figure 1B). The
strain ∆fmaA::fmaA secreted an average concentration of 0.25 µg/mL fumagillin, although
the concentration of fumagillin secreted was higher than that produced by the Wt in 25%
of the assays. These results suggested great variability in fumagillin production by the WT
and ∆fmaA::fmaA strains during growth.
In order to study any effect of exogenous fumagillin on A. fumigatus, a growth and
germination assay of the Wt, ∆fmaA, and ∆fmaA::fmaA in the presence of 0.5, 1, and
2 µg/mL of fumagillin was performed. The results showed that fumagillin did not inhibit
fungal growth (Figure S2) and that germination of the three strains was similar, being
increased in the presence of the toxin (Figure 1B–D). Moreover, the addition of fumagillin
was statistically correlated with the emergence of two germination tubes/conidium at 8 h
of incubation. This effect was more pronounced on the fumagillin non-producer strain
than on the Wt and ∆fmaA::fmaA strains (Figure 1B–D).
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cial fumagillin (0.2 µg/mL) as an internal control. (* p < 0.05). (B–D) Germination and double branch assay of the Wt, 
ΔfmaA, and ΔfmaA::fmaA, respectively, after 8 h of exposition to 0.5, 1, and 2 µg/mL of fumagillin. All the experiments 
were done in triplicate in three independent assays. Significant differences respect to the control without the toxin are
represented (* p < 0.05, *** p < 0.001). 
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phages (RAW 264.7) or lung epithelial cells (A549) were exposed to the toxin for 24 h (Fig-
ure 2). Our data showed that about 10% of the fumagillin disappeared from the culture
medium even in the absence of any of the cell lines, likely due to degradation processes. 
On the other hand, in the wells with macrophages, a higher progressive reduction in fum-
agillin concentration in the culture medium was detected, being 23.5% less after 24 h of 
exposition. More surprising were the results obtained in wells with epithelial cells, where 
a 93.5% of the initially added fumagillin was lost in the same period. Furthermore, we 
Figure 1. Fung l trains fumagillin production ability and self-resistance to the toxin. (A) Quantification of fumagillin
secretion by the three A. fumigatus str ins after 48 h of incubation in complete RPMI measured by UHPLC using commercial
fumagillin (0.2 µg/mL) as an internal c tr l. (* . ). ( ) er ination and double branch assay of the Wt, ∆fmaA,
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3.2. Different Fumagillin Uptake Ability in Cell Lines
Since toxins need to be in contact with their target to fulfill their function, we measured
fumagillin concentration dynamics by UHPLC in the culture medium when macrophages
(RAW 264.7) or lung epithelial cells (A549) were exposed to the toxin for 24 h (Figure 2).
Our data showed that about 10% of the fumagillin disappeared from the culture medium
even in the absence of any of the cell lines, likely due to degradation processes. On the
other hand, in the wells with macrophages, a higher progressive reduction in fumagillin
concentration in the culture medium was detected, being 23.5% less after 24 h of exposition.
More surprising were the results obtained in wells with epithelial cells, where a 93.5% of
the initially added fumagillin was lost in the same period. Furthermore, we were able to
recover fumagillin, 30 ± 14 µg/L and 21 ± 4 µg/L from the pellet of cells treated with
RIPA buffer of A549 and RAW 264.7 culture, respectively, after exposur to 2 mg/L of
fumagillin (Figure S3). No degradation forms of this m l cule w re detected either in the
cult re supernatant or in extractions f lysed cells.
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Figure 2. Quantification of the fumagillin absorption ability of each ell line. Fumagillin (1 µg/mL in
complete RPMI) was added to empty wells (black line) or w lls containing either A549 (dark grey) or
RAW 264.7 cells (light grey), and its concentration was determined at 8, 20, and 22 h after inoculation
by UHPLC. The total loss of fumagillin concentration after 24 h of exposition, compared to the initial
concentration, is represented in percentage on the right axis of the graph (vertical dot lines). All the
experiments were done in triplicate in three independent assays (* p < 0.05).
3.3. a illi I d ces a ecrease in ellular ctivity and a elay in Proliferation in Lung
Epithelial Cells
o evaluate the effect of fumagillin on the electron transport chain (ETC) activity of
549 epithelial cells, TT reduction assays ere perfor ed (Figure 3A). ETC activity as
lo er i cells gro ing for 24 h in the presence of fumagillin at any of the concentrations
tested in co parison ith those gro ing ithout fumagillin. In contrast, the staining ith
propidium iodide showed no changes in cell viability, with about 75% of cells being viable
after 24 h of incubation in all conditions tested (Figure 3B).
The proliferation and igration abilities of A549 cells in the presence of the toxin
were also studied using the wound healing assay. Notably, fumagillin inhibited the ability
of epithelial cells to close the gap caused in the monolayer by a pipette tip after 24 h
of incubation with all the fumagillin concentrations tested. The results were even more
pronounced after 48 h of incubation (Figure 3C), where only a wound closure of around
20% was measured in the cultures with the mycotoxin, while in control cells, it was
completely closed.
Finally, cell proliferation was studied by flow cytometry in cells exposed to fumagillin,
showing a similar delay after 48 h of exposition to all the fumagillin concentrations tested
(Figure 3D). In contrast, after 72 h, a marked fumagillin concentration-dependent effect
was detected. At this time, in both control and treated cells, two peaks of fluorescence
were observed, corresponding to two different cell generations. The overlay graph with
the different concentrations of fumagillin (Figure 3E) demonstrates that exposure to the
toxin was critical for the development of the second generation of cells. In fact, the number
of cells detected in this phase when they were incubated with 2 µg/mL of fumagillin
was 8% less than with 0.5 µg/mL. Finally, it is important to highlight that the differences
shown in the cell proliferation panel (both after 48 and 72 h of treatment) (Figure 3D) were
statistically significant when the average fluorescence of each condition was compared
(Figure 3F).
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3.4. Fumagillin Reduces Cellular Activity and Viability of Macrophages
Similar to what we observed in epithelial cells, the ETC activity of RAW 264.7 macr phages
were significantly lower after 24 h of incubation with 1 and 2 µg/mL of fumagillin in com-
parison with those without mycotoxin and even with 0.5 µg/mL (Figure 4A). Moreover, the
propidium iodide assay showed a significant reduction in cell viability in the presence of all
the fumagillin concentrations used (Figure 4B).
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The proliferation analysis also showed a slight delay in cell proliferation after 48 and
72 h of toxin exposition in comparison with the control cells without fumagillin (Figure 4C),
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but this effect was not concentration-dependent (Figure 4D). As happened with A549
cells, the differences shown in the cell proliferation panel (Figure 4C)) were statistically
significant when the average fluorescence of each condition was compared (Figure 4E).
3.5. The Loss of the Ability to Produce Fumagillin Is Associated with a Transient Higher Rate of
Phagocytosis of A. fumigatus Conidia
In order to understand whether fumagillin secretion can alter the interaction between
the fungus and macrophages, we performed co-cultures using the three fungal strains and
either BMMs or RAW 264.7 cells and we analyzed the fungal germination and branching
rates, as well as the phagocytosis index. Concerning germination, no differences between
strains were found neither in control nor when the fungus was in contact with RAW 264.7
cells. However, in the presence of BMMs, the germination rates of ∆fmaA and ∆fmaA::fmaA
strains were significantly higher than those of Wt at 6 h, reaching the same value at 8 h in all
the strains (Figure 5A–C). Moreover, the development of the second branch of the hyphae
of the fumagillin non-producer strain was significantly higher than those observed for Wt
and ∆fmaA::fmaA when exposed to macrophages (Figure 5D–F) as observed previously in
fumagillin contact studies.
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(Figure 6B). Comparing the untreated assay (Figure 6A) with the pre-treated assay (Figure 
6B), we found that the pre-treated cells showed significantly lower phagocytosis rates af-
ter 6 and 8 h of co-incubation (solid triangles). This may imply that macrophages were 
affected by the pre-treatment, showing lower phagocytic ability. The phagocytosis study 
performed using heat-inactivated conidia of the three strains did not show differences 
between these fungal strains (Figure 6C). As the phagocytosis rate of the ∆fmaA strain by 
BMMs was the most efficient during the first 6 h (Figure 6D), we studied TNF production 
in these co-cultures. Overall, there was a trend showing that the ∆fmaA strain stimulated 
a lower TNF release by BMMs in all the time points analyzed, although a great biological 
variability between replicates was observed. Specifically, at 4 h, ∆fmaA and ∆fmaA::fmaA 
showed a significantly lower capacity to induce TNF production by BMMs than the Wt. 
Figure 5. Growth dynamics of f ngal strains in c -incubation with macrophages. Data of fungal
germination (%), double branch germination (%), and hyphal length after 8 h of incubation of the
three fungal strains growing either alone (A,D,G) (Control), in co-culture with BMMs (B,E,H), or in
co-culture with RAW 264.7 macrophages (C,F,I). * p < 0.05.
Regarding hyphal length, the ∆fmaA and ∆fmaA::fmaA strains grew significantly longer
hyphae than the Wt when the fungus grew alone or in co-culture with BMMs (Figure 5G,H).
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On the other hand, no differences in hyphal length were found between strains when they
grew in the presence of RAW 264.7 macrophages (Figure 5I).
Finally, we analyzed the macrophage phagocytosis of fungal cells for 8 h and observed
that the ∆fmaA strain was phagocytosed at a significantly higher rate during the first 4 h of
contact with both RAW 264.7 and BMMs cells (Figure 6A,D, respectively). However, there
were no significant differences in the phagocytosis at 6 and 8 h. The pre-treatment of RAW
264.7 cells with fumagillin before the co-incubation with the fungal strains only showed
a significant increase in phagocytosis of the non-fumagillin producer strain (Figure 6B).
Comparing the untreated assay (Figure 6A) with the pre-treated assay (Figure 6B), we
found that the pre-treated cells showed significantly lower phagocytosis rates after 6 and
8 h of co-incubation (solid triangles). This may imply that macrophages were affected by the
pre-treatment, showing lower phagocytic ability. The phagocytosis study performed using
heat-inactivated conidia of the three strains did not show differences between these fungal
strains (Figure 6C). As the phagocytosis rate of the ∆fmaA strain by BMMs was the most
efficient during the first 6 h (Figure 6D), we studied TNF production in these co-cultures.
Overall, there was a trend showing that the ∆fmaA strain stimulated a lower TNF release
by BMMs in all the time points analyzed, although a great biological variability between
replicates was observed. Specifically, at 4 h, ∆fmaA and ∆fmaA::fmaA showed a significantly
lower capacity to induce TNF production by BMMs than the Wt. The significantly higher
production of TNF by the BMMs in contact with ∆fmaA::fmaA compared to the Wt and
∆fmaA strain after 8 h of co-incubation (Figure 6E) was surprising.
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3.6. Fumagillin Synthesis Increases Fungal Load during Infection
To evaluate the importance of fumagillin production for A. fumigatus virulence in vivo,
we used a mouse model of pulmonary aspergillosis already established in our lab [23].
Figure 7A shows that the ∆fmaA strain induced a 50% mortality in the first 4 days post-
infection, but mice that survived after this day remained alive throughout the experiment.
In contrast, the mice infected with the Wt showed a more progressive increase in mortality
rate reaching 60% at the end of the experiment. Finally, it is important to highlight that the
∆fmaA::fmaA strain was significantly more lethal than the Wt and ∆fmaA strain. Considering
the biological variability observed in the concentration of fumagillin secreted by the strains,
the conidia suspensions used for the infections were for their specific ability to produce
fumagillin by UHPLC at the same time. This revealed that the ∆fmaA::fmaA cells used in
these in vivo experiments were able to produce more fumagillin than the Wt strain, but
the differences were not statistically significant. The ∆fmaA strain used did not produce
fumagillin, as expected.
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The fungal burden was slightly higher in mice infected with the ∆fmaA than in the
others (F gure 7B). H wever, the average fungal burden of the mice inf cted with ∆fmaA
was measured from the 50% of mice died during the first four days, which presented high
CFUs values because, surpr singly, in the lungs of almost all the mice (4 out of 5) that
survived the experi ent, CFUs were not found. In contrast, mice infected with the Wt
and the ∆fmaA::fmaA strains presented variable CFUs cou ts without a clear relationship
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between the day of the death and the fungal burden, and even survivor mice presented
high CFUs values, except for one.
Finally, the symptoms of the infected mice were monitored using a scale of 0 to 10,
showing that mice infected with the ∆fmaA::fmaA strain presented significantly more severe
symptomatology than those infected with the Wt and the ∆fmaA strain (Figure 7C). From
day 16 to the end of the experiment, the clinical score values were similar between all the
groups. In contrast to the clinical score, mice weight (Figure 7D) was the same regardless
of the fungal strain used to infect the mice.
4. Discussion
The importance of gliotoxin for A. fumigatus virulence has been widely described [12–15,30–33].
However, the relevance of other toxins produced by A. fumigatus, such as fumagillin, has not been
studied in depth.
Fumagillin is a macrolide that targets methionine aminopeptidase 2 (MetAP2) by
covalent binding to the His231, inhibiting the proper functioning of the protein. Recent
publications have pointed out that fumagillin could induce lung epithelial cell damage,
both acting alone [23] and in synergy with gliotoxin [34]. Moreover, this mycotoxin is
able to inhibit cell proliferation and angiogenesis in endothelial cells [20]. However, little
is known about its effect on the fungus or other cell types or its role in fungal virulence
in vivo during the development of pulmonary aspergillosis.
To study this, we used a deletion mutant strain of the fmaA gene and its complement
strain where fmaA encodes a terpene cyclase required for fumagillin synthesis [22]. First, an
UHPLC method for the detection of fumagillin in samples of RPMI obtained after in vitro
assays was standardized. Using this method, we were able to detect as low as 0.1 µg/mL
of fumagillin. Furthermore, we confirmed that the ∆fmaA strain was not able to secrete
fumagillin, corroborating the previously published data [22].
Then, we performed a macroscopic phenotypical and growth study that showed that
the mutant strain ∆fmaA did not present any difference compared to the Wt strain when
they grew in the presence of structural, osmotic, and oxidative stresses (Figures S1 and S3).
We also observed that A. fumigatus was not susceptible to exogenous fumagillin (Figure S2),
but that fumagillin may be a germination-stimulating factor (Figure 1). These results could
support our hypothesis that the gene Afu8g00410, encoding a methionine aminopeptidase
located inside the fumagillin cluster, confers resistance to the fungus. This gene would be
co-expressed with the rest of the cluster, providing a resistant MetAP2 to the fungus and
may explain the results obtained in Figure 1. Continuing with fungal strains’ germination
ability, it is notable that the ∆fmaA strain reached higher germination and branching
rates than the other strains growing without cells and in the presence of fumagillin. The
increased branching rates observed in the ∆fmaA strain may indicate that fumagillin could
be involved in a polarization process, or in contrast, the increased branching observed
could be a consequence of the adaptive process to the fumagillin presence. In any case,
both hypotheses should be studied in depth.
Analysis of the effect of synthetic fumagillin on both A549 pneumocytes and RAW
264.7 macrophages, which are common cell lines to perform toxin/molecule/drug response
analysis [23,34,35], demonstrated that each cell type uptakes the mycotoxin in different
ways (Figure 2). Fumagillin was clearly depleted from the supernatant (93.5%) of pneu-
mocytes but to a much lesser degree (23.5%) macrophages culture. Furthermore, the lysis
of both cell types using RIPA buffer and subsequent detection of the toxin by UHPLC
suggested that the reduction in fumagillin from the media was due to its uptake by the
cell. One explanation could be attributed to the different expression levels of the MetAP2
enzyme between both cell types (https://www.proteinatlas.org; accessed 15 August 2021).
Moreover, we cannot forget that macrophages can express different efflux systems that
could expel the toxin from the cytosol. Finally, we cannot totally discard that cells could
also degrade fumagillin, but no peaks similar to the ones observed after the fumagillin
degradation assays (light, temperature, and acid environment) were detected either in the
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supernatants or the pellets (Figure S2). Therefore, it seems that fumagillin could passively
cross the cell membrane reaching the cell cytosol [36] and bind to MetAP2, thus leading to
loss of the toxin in the supernatant.
The MTT results shown in this study are in accordance with the ones previously
published [34,37,38], but our interpretation of the MTT results varies with the other studies.
In this study, we used the MTT assay as a technique suitable to measure the ETC [39],
while other authors used it to measure cell viability. On the other hand, it is important to
note that our highest fumagillin concentration used (2 µg/mL) was the lowest of all these
above-cited studies. In contrast, it is important to note that during the infection process
in vivo or during the contact between the fungus and host cells, the toxin concentration
reached could be higher. For instance, the production of candidalys in by Candida albicans
in the invasion pocket produced an extremely high concentration of the toxin at the contact
site between the fungus and the cell [40]. This hypothesis could explain why a previous
study performed with this same ∆fmaA strain demonstrated that it was less toxic than the
Wt to the A549 cell line as assessed by 51Cr release assays [23].
Our results support the affectation of the ETC activity, as both the wound healing
assay and the CFSE analysis performed by flow cytometry demonstrated that the prolifera-
tion of epithelial cells was affected after fumagillin exposure but not its cellular viability.
Specifically, the covalent binding of fumagillin to its molecular target, MetAP2, results in
an inhibition of all functions that MetAP2 orchestrates inside the cell [21]. They include the
membrane signaling pathway involving proteins, such as Gi/o, Giβγ, PI3K, PLC, DAG, or
IP3 that govern cell migration and proliferation [41–43].
The results obtained with the RAW 264.7 cells were slightly different from those ob-
tained from the pneumocytes since although they suffered a drop in the ETC activity and a
delay in the cell proliferation after exposure to fumagillin, the effect was less marked than
observed in pneumocytes and was not dependent on concentration. These results are appar-
ently in contradiction with previous studies of other authors on rat alveolar macrophages
using trypan blue to measure cell viability, which is a less sensitive method [44]. Currently,
it is unknown why macrophages, but not epithelial cells die at such a high rate; the different
effects of the fumagillin depending on the cell type might be explained because the MetAP2
concentration could vary among tissues and cell types (https://www.proteinatlas.org;
accessed 15 August 2021).
In addition, fumagillin seems to protect, at least in early hours, the fungus from
phagocytosis as assessed from increased phagocytosis of ∆fmaA conidia. In fact, when
RAW 264.7 phagocytic cells were pre-treated with fumagillin, the phagocytic ability of
these cells was significantly decreased after 6 and 8 h of co-incubation in comparison with
the phagocytosis rates at this same time points of the cells untreated. Furthermore, the
phagocytosis of the cells pre-treated was still significantly higher in contact with ∆fmaA
strain at all times. These results, alongside the evidence that phagocytosis of the heat-
inactivated conidia is similar in mutants and Wt strains, points out that the inhibition of
the phagocytosis observed is because of the toxin effect over the macrophages and not
because of an external structure defect of the conidia cell wall produced as a consequence
of the genetic manipulation of the fungal strains. Moreover, it is important to note that
the fumagillin produced by the Wt and complemented strains could be modulating the
macrophages’ ETC and viability influencing the cell response, from their phagocytosis
ability to TNF production. Indeed, TNF induction by BMMs was also overall lower in
response to the ∆fmaA strain than to the Wt and complemented strains, although it was
not statistically significant except at 4 h.
Regarding in vivo assays, Liu and coworkers evaluated the virulence ability of the
mutant A. fumigatus non-fumagillin producer strain ∆fumR [24]. For that, they used a
corticosteroid immunosuppressed mice model, and they did not describe any virulence
difference between the mutant and the Wt strain. Therefore, and due to the differences in
the phagocytosis assays observed (Figure 6), we wanted to assess a neutropenic murine
aspergillosis model to look at the role of the fmaA gene in virulence. Unexpectedly, the
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∆fmaA::fmaA strain was significantly more lethal than the Wt and ∆fmaA strains. In contrast,
the lowest mortality rate (although not significantly different to the Wt) was observed in
those mice infected with the ∆fmaA strain.
On the other hand, the CFUs analysis showed that most of the surviving mice infected
with ∆fmaA strain did not contain viable fungus in their lungs, whereas a high fungal
burden was detected in mice infected with the other strains at the end of the experiment.
These results may indicate that the mortality caused by ∆fmaA, only observed during the
first four days of infection, could be the result of the ability of this mutant to germinate
faster than the others. Furthermore, the possible production of other virulence factors,
such as proteases or other toxins, could be compensating for the lack of fumagillin, but this
hypothesis has not been analyzed in this study.
To our knowledge, this is not the first fumagillin research, but it is the first in-depth
study of the role of fumagillin on A. fumigatus virulence, showing that this molecule
can affect host cell homeostasis and that A. fumigatus shows an intrinsic resistance to
its own toxin. Finally, in our murine model, whereas we found that mice infected with
∆fmaA survived with lower fungal burden than those infected with the wild type or
the complemented strain, there was little overall difference in virulence dependent on
this toxin.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/jof7110936/s1, Figure S1: Phenotypic characterization of fumagillin mutant strains; Fig-
ure S2: Growth curves of the fungal strains after exposition to 0, 0.5, 1, and 2 µg/mL of fumagillin for
70 h; Figure S3: Fumagillin detection and its degradative products by UHPLC; Figure S4: Inhibition
assay of the fungal strains exposed to 30%, 15%, 7.5%, and 3.75% of H2O2 for 48, 75, and 96 h; Table S1:
Clinical scoring table.
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